Click image to view it in full size

The DCT market has been a nascent market prior to the COVID-19 pandemic. The accelerated adoption witnessed during the outbreak of the pandemic in 2020 was mainly due to restricted mobility of site investigators, clinical research associates and patients to participate in the trials. To ensure patient safety most sponsors and CROs adopted digital tools to support trial operations that included telemedicine, remote source data verification and sensor/ mobile technology enabled direct data capture solutions. Recent initiatives conducted by the Decentralized Trials & Research Alliance has increased awareness of DCTs globally and catapulted their adoption especially in North America. The evolving regulation supporting the ease of implementing technologies that enable decentralized clinical trials delivery in Europe and other regions is estimated to drive the adoption going forward.